Navigation Links
NCCN Receives $4 Million Oncology Research Grant from Wyeth
Date:1/15/2009

NCCN recently received a $4 million research grant from Wyeth Pharmaceuticals to evaluate the safety and effectiveness of temsirolimus in the treatment of solid tumors. Temsirolimus is currently approved to treat advanced renal cell carcinoma (RCC). This grant is the largest research award received by NCCN to date. Investigators from NCCN Member Institutions are eligible to apply for the research funding.

FORT WASHINGTON, Pa., Jan. 15 /PRNewswire-USNewswire/ -- The National Comprehensive Cancer Network (NCCN) has been awarded a $4 million grant from Wyeth Pharmaceuticals to support clinical studies of temsirolimus (Torisel(R), Wyeth) in the treatment of solid tumors. This is the largest individual research grant that NCCN has received since the inception of its Oncology Research Program in 1999.

Temsirolimus is a targeted therapy approved to treat advanced renal cell carcinoma (RCC), a type of cancer that originates in the kidney. Clinical trials supported by this grant will evaluate the effectiveness of temsirolimus in solid tumors, including but not limited to, breast, endometrial, head and neck, hepatocellular, hormone-refractory prostate, non-small cell lung, and ovarian cancers.

"This grant represents the largest research award to date for NCCN and is an outstanding achievement," says William T. McGivney, PhD, Chief Executive Officer, NCCN. "The funding not only helps accelerate potentially life-saving research in the field of cancer, but also creates a collaborative opportunity for investigators from NCCN Member Institutions. Obtaining major research grants represents yet another way in which NCCN lives out our mission of improving the quality and effectiveness of care provided to patients with cancer."

Temsirolimus is the only commercially available inhibitor of mammalian target of rapamycin (mTOR). The mTOR signaling pathway regulates cell growth and promotes angiogenesis, a physiolo
'/>"/>

SOURCE National Comprehensive Cancer Network
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
2. DaVita Receives Civil Complaint
3. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
4. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
5. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
6. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
7. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
8. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
9. Prime Therapeutics Receives TIPPS Certification
10. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
11. UCLA receives $22.5 million to explore the fundamental biology of mental disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... Eldermark ... for LeadingAge’s Center for Aging Services Technologies (CAST) Medication Management Technologies whitepaper. The ... post-acute care providers understand the benefits of using medication management technologies . ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... Hospital's Karmanos Center for Natural Birth . The Karmanos Center for ... safe natural childbirth experience. With nurses and caregivers that are trained in holistic ...
(Date:7/31/2015)... ... July 31, 2015 , ... New Energy Works Timberframers ... Amphitheater in McMinnville, Oregon August 15th, 2015 from 9am – 12pm. Timber frame ... important day for the entire community as the culmination of months of effort, planning, ...
(Date:7/31/2015)... ... July 31, 2015 , ... An article entitled ... talked about a woman’s unfortunate experience having cosmetic skin procedures done by a ... resulted in blistering, swelling, bruising, and pain. This woman’s experience is only one ...
(Date:7/31/2015)... ... July 31, 2015 , ... In the most recent testosterone ... in the Northern District of Illinois, Androgel testosterone attorneys report that a “Mini Status ... entry was made recording the minutes of the status conference, which was held that ...
Breaking Medicine News(10 mins):Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 3Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 2Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 3Health News:Dermatologists Discuss Rise in Unqualified Practitioners of Cosmetic Dermatology 2Health News:Dermatologists Discuss Rise in Unqualified Practitioners of Cosmetic Dermatology 3Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 2Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 3Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 4
... Joins Thousands of Participants in Inspirational Closing Ceremony; ... Breast Cancer Organizations, WASHINGTON, May 4 ... Reese Witherspoon was a special guest at the,sixth ... this weekend,cheering on and joining walkers on their ...
... to an expanding waist line, weight gain and a tendency ... of a study published today in the journal Nature Genetics. ... is significantly more common in those with Indian Asian than ... Heart Foundation, could lead to better ways of treating obesity. ...
... knowledge gap, experts say , , SUNDAY, May 4 (HealthDay ... surprisingly low knowledge of child development, including basic concepts ... should act, a new study finds. , For instance, ... 1-year-olds can,t tell the difference between right and wrong, ...
... Study shows only 49% intended to do so if child ... News) -- New research shows that only half of American ... papillomavirus (HPV) if the girls are under the age of ... which is sexually transmitted, is the primary cause of cervical ...
... assumptions, children are more vulnerable to the harmful effects ... they are in early childhood, according to a Cincinnati ... 4 at the annual meeting of the Pediatric Academic ... protecting toddlers from lead exposure, our study shows that ...
... U.S. parents have a surprisingly low-level knowledge of ... childs physical, social and emotional growth, according research ... which suggest that such false parenting assumptions can ... kids of much-needed cognitive stimulation, will be presented ...
Cached Medicine News:Health News:Reese Witherspoon Helps Celebrate Avon Walk for Breast Cancer Washington, D.C. - Weekend-Long Event Raises $8.1 Million 2Health News:Reese Witherspoon Helps Celebrate Avon Walk for Breast Cancer Washington, D.C. - Weekend-Long Event Raises $8.1 Million 3Health News:Reese Witherspoon Helps Celebrate Avon Walk for Breast Cancer Washington, D.C. - Weekend-Long Event Raises $8.1 Million 4Health News:Reese Witherspoon Helps Celebrate Avon Walk for Breast Cancer Washington, D.C. - Weekend-Long Event Raises $8.1 Million 5Health News:Reese Witherspoon Helps Celebrate Avon Walk for Breast Cancer Washington, D.C. - Weekend-Long Event Raises $8.1 Million 6Health News:Gene sequence that can make half of us fatter is discovered 2Health News:One-Third of Parents Lack Facts About Child Development 2Health News:One-Third of Parents Lack Facts About Child Development 3Health News:Many Moms Unwilling to Have Younger Daughters Get HPV Vaccine 2Health News:Many Moms Unwilling to Have Younger Daughters Get HPV Vaccine 3Health News:Children more vulnerable to harmful effects of lead 2Health News:Nearly one-third of US parents don't know what to expect of infants 2
(Date:7/31/2015)... 31, 2015 Magnaquest, a ... data and cloud computing operators has signed a ... giant for Internet of Things (IoT) related initiative. ... on subscription model.      (Logo: ... striving for business innovations to make healthcare services ...
(Date:7/30/2015)... VIEW, Calif. , July 30, 2015 ... it will release its second quarter 2015 financial results ... 2015.   In conjunction with the release, the Company ... at 5:00 p.m. Eastern Time on ... of the quarter and other business developments. ...
(Date:7/30/2015)... edition of #MedicareMonday on Medicare,s 50 th anniversary. As Medicare celebrates 50 years, ... the success of the prescription drug benefit, commonly referred to as Part D. ... videos here: http://onphr.ma/1INp9qQ ... ... More ...
Breaking Medicine Technology:Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3
... in Combination with Chemotherapy, FREMONT, Calif. ... pharmaceutical company discovering and developing novel,RNA interference ... Research published results on efficacy of siRNA ... lung cancer (NSCLC) in,the edition dated October ...
... Pivotal Data Show Prophylaxis Treatment with Kogenate FS ... in Children with No Pre-Existing,Joint Damage, BERKELEY, ... that the U.S. Food and Drug Administration (FDA) ... to reduce the frequency of bleeding episodes and ...
Cached Medicine Technology:Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 2Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 3Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 4FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 2FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 3FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 4FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 5
Khosla Precision and Quality in Medical and Surgical Products....
Khosla Precision and Quality in Medical and Surgical Products....
Khosla Precision and Quality in Medical and Surgical Products....
Manual Table For Slit Lamp...
Medicine Products: